Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical NT-077 (tiotropium bromide) safety, pharmacokinetics, and sweat-response study in healthy male volunteers
NL-OMON50872Active, not recruiting
- Sponsor
- Xero Pharmaceuticals
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of NT-077 and tiotropium in essential axillary hyperhidrosis and Primary hyperhidrosis (PH), sponsored by Xero Pharmaceuticals. Primary endpoints: Plasma concentration-time profile, AUC0-t and 5 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
NT-077tiotropium
03
Conditions
essential axillary hyperhidrosisPrimary hyperhidrosis (PH)
Beyond the preview
Go deeper on NL-OMON50872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50872.